S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

$3.23
+0.07 (+2.22%)
(As of 03/1/2024 ET)
Today's Range
$3.12
$3.55
50-Day Range
$1.43
$3.23
52-Week Range
$0.50
$3.89
Volume
3.69 million shs
Average Volume
2.89 million shs
Market Capitalization
$603.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.71

Taysha Gene Therapies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.9% Upside
$5.71 Price Target
Short Interest
Bearish
8.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of Taysha Gene Therapies in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.63) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.93 out of 5 stars

Medical Sector

667th out of 951 stocks

Biological Products, Except Diagnostic Industry

105th out of 151 stocks


TSHA stock logo

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

TSHA Stock Price History

TSHA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
DXCM, CDW and VRM are among after hour movers
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TSHA Jul 2024 7.500 call
TSHA Jul 2024 7.500 put
Taysha Gene Therapies Inc.
TSHA Feb 2024 1.500 call
TSHA Feb 2024 1.500 put
Taysha Gene Therapies Inc (TSHA)
Taysha: Produces Solid Data But Has Abandoned Programs
See More Headlines
Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/03/2024
Next Earnings (Estimated)
3/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
65
Year Founded
2020

Price Target and Rating

Average Stock Price Target
$5.71
High Stock Price Target
$8.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+76.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-166,010,000.00
Net Margins
-1,498.57%
Pretax Margin
-1,494.08%

Debt

Sales & Book Value

Annual Sales
$2.50 million
Book Value
$0.02 per share

Miscellaneous

Free Float
182,753,000
Market Cap
$603.88 million
Optionable
Optionable
Beta
0.29

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Sean P. NolanMr. Sean P. Nolan (Age 56)
    CEO & Chairman
    Comp: $674k
  • Dr. Sukumar Nagendran M.D. (Age 57)
    President, Head of Research & Development and Director
    Comp: $619.1k
  • Mr. Kamran Alam CPAMr. Kamran Alam CPA (Age 46)
    M.B.A., CFO & Corporate Secretary
    Comp: $703.61k
  • Hayleigh Collins
    Director & Head of Corporate Communications
  • Ms. Tracy M. Porter SPHR
    Chief People Officer
  • Mr. Frederick Porter Ph.D.
    Chief of Staff & Technical Operations Officer
  • Ms. Emily McGinnis M.P.H.
    Chief Patient Advocacy & External Affairs Officer
  • Mr. Sean McAuliffe
    Chief Business Officer
  • Dr. Steven Gray Ph.D.
    Chief Scientific Advisor of UT Southwestern Gene Therapy Program
  • Berge Minassian M.D.
    Chief Medical Advisor of UT Southwestern Gene Therapy Program














TSHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TSHA shares.
View TSHA analyst ratings
or view top-rated stocks.

What is Taysha Gene Therapies' stock price target for 2024?

7 analysts have issued 1-year target prices for Taysha Gene Therapies' stock. Their TSHA share price targets range from $4.00 to $8.00. On average, they expect the company's share price to reach $5.71 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts price targets for TSHA
or view top-rated stocks among Wall Street analysts.

How have TSHA shares performed in 2024?

Taysha Gene Therapies' stock was trading at $1.77 at the beginning of 2024. Since then, TSHA shares have increased by 82.5% and is now trading at $3.23.
View the best growth stocks for 2024 here
.

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our TSHA earnings forecast
.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.33. During the same quarter last year, the firm earned ($1.28) EPS.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.31%), Avoro Capital Advisors LLC (2.33%), Point72 Asset Management L.P. (1.44%), Price T Rowe Associates Inc. MD (0.66%), Price T Rowe Associates Inc. MD (0.66%) and Exome Asset Management LLC (0.37%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends
.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSHA) was last updated on 3/3/2024 by MarketBeat.com Staff